Skip to main content
. 2018 Apr 16;36(16):1619–1627. doi: 10.1200/JCO.2017.76.5941

Fig 2.

Fig 2.

Incremental cost-effectiveness estimates of Oncotype DX (ODX; node-negative breast cancer) (A) according to industry relationship and (B) in US versus non-US analyses. (For comparison purposes, we chose only studies that reported ODX cost effectiveness for estrogen receptor–positive, node-negative breast cancer in their base-case analyses.)